Allometric issues in drug development
Related Experiment Video
Updated: Oct 18, 2026

Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues
Published on: April 7, 2023
1Office of Clinical Pharmacology and Biopharmaceutics, Division of Pharmaceutical Evaluation I (HFD-860), Food & Drug Administration, Woodmont Office Center II, Room 4079, 1451 Rockville Pike, Rockville, Maryland 20852, USA. Mahmoodi@CDER.FDA.GOV
Abstract:
The concept of correlating pharmacokinetic parameters with body weight from different animal species has become a useful tool in drug development. The allometric approach is based on the power function, where the body weight of the species is plotted against the pharmacokinetic parameter(s) of interest. Clearance, volume of distribution, and elimination half-life are the three most frequently extrapolated pharmacokinetic parameters. Over the years, many approaches have been suggested to improve the prediction of these pharmacokinetic parameters in humans from animal data. A literature review indicates that there are different degrees of success with different methods for different drugs. Overall, though interspecies scaling requires refinement and better understanding, the approach has lot of potential during the drug development process.
Related Concept Videos
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Preclinical Development: Overview
Factors Affecting Drug Response: Overview
Drug Discovery: Overview
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Drug Toxicity: Risk factors

